First PREMIER Bank Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

First PREMIER Bank lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 533 shares of the company’s stock after selling 28 shares during the quarter. First PREMIER Bank’s holdings in Eli Lilly and Company were worth $472,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its holdings in Eli Lilly and Company by 14.4% during the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 1,393 shares of the company’s stock valued at $1,234,000 after acquiring an additional 175 shares during the period. Sovereign Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 3.8% in the 3rd quarter. Sovereign Financial Group Inc. now owns 683 shares of the company’s stock worth $605,000 after buying an additional 25 shares during the period. Strategic Wealth Partners Ltd. lifted its holdings in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. Strategic Wealth Partners Ltd. now owns 11,942 shares of the company’s stock worth $10,580,000 after buying an additional 455 shares during the period. Rockingstone Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 24.5% in the 3rd quarter. Rockingstone Advisors LLC now owns 305 shares of the company’s stock worth $270,000 after buying an additional 60 shares during the period. Finally, Hoxton Planning & Management LLC lifted its holdings in shares of Eli Lilly and Company by 17.0% in the 3rd quarter. Hoxton Planning & Management LLC now owns 1,358 shares of the company’s stock worth $1,203,000 after buying an additional 197 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.3 %

Shares of NYSE:LLY opened at $916.04 on Wednesday. The business’s 50-day moving average is $904.41 and its 200 day moving average is $850.31. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The firm has a market capitalization of $870.61 billion, a P/E ratio of 134.57, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on LLY shares. Truist Financial reiterated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Citigroup began coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price for the company. Bank of America upped their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.